Notice: This company has been marked as potentially delisted and may not be actively trading. TradeUP Acquisition (UPTD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends UPTD vs. BCLI, ONVO, KLTO, CELZ, BCDA, FRTX, TTNP, CHRO, GENE, and ALBTShould you be buying TradeUP Acquisition stock or one of its competitors? The main competitors of TradeUP Acquisition include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Klotho Neurosciences (KLTO), Creative Medical Technology (CELZ), BioCardia (BCDA), Fresh Tracks Therapeutics (FRTX), Titan Pharmaceuticals (TTNP), Chromocell Therapeutics (CHRO), Genetic Technologies (GENE), and Avalon GloboCare (ALBT). These companies are all part of the "biological products, except diagnostic" industry. TradeUP Acquisition vs. Brainstorm Cell Therapeutics Organovo Klotho Neurosciences Creative Medical Technology BioCardia Fresh Tracks Therapeutics Titan Pharmaceuticals Chromocell Therapeutics Genetic Technologies Avalon GloboCare TradeUP Acquisition (NASDAQ:UPTD) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation. Which has more volatility and risk, UPTD or BCLI? TradeUP Acquisition has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Does the media refer more to UPTD or BCLI? In the previous week, Brainstorm Cell Therapeutics had 4 more articles in the media than TradeUP Acquisition. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 0 mentions for TradeUP Acquisition. Brainstorm Cell Therapeutics' average media sentiment score of 0.96 beat TradeUP Acquisition's score of 0.67 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment TradeUP Acquisition Positive Brainstorm Cell Therapeutics Positive Do analysts recommend UPTD or BCLI? Brainstorm Cell Therapeutics has a consensus price target of $30.00, indicating a potential upside of 2,554.87%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than TradeUP Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TradeUP Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in UPTD or BCLI? Brainstorm Cell Therapeutics received 291 more outperform votes than TradeUP Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformTradeUP AcquisitionN/AN/ABrainstorm Cell TherapeuticsOutperform Votes29161.39% Underperform Votes18338.61% Do insiders and institutionals hold more shares of UPTD or BCLI? 35.0% of TradeUP Acquisition shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 55.1% of TradeUP Acquisition shares are owned by insiders. Comparatively, 6.7% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger earnings & valuation, UPTD or BCLI? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTradeUP AcquisitionN/AN/A-$1MN/AN/ABrainstorm Cell TherapeuticsN/AN/A-$17.19M-$3.45-0.33 Is UPTD or BCLI more profitable? Company Net Margins Return on Equity Return on Assets TradeUP AcquisitionN/A N/A -3.38% Brainstorm Cell Therapeutics N/A N/A -373.68% SummaryBrainstorm Cell Therapeutics beats TradeUP Acquisition on 7 of the 11 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get TradeUP Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for UPTD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPTD vs. The Competition Export to ExcelMetricTradeUP AcquisitionBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82M$3.08B$5.33B$8.88BDividend YieldN/A1.76%4.98%4.04%P/E RatioN/A46.38131.8417.44Price / SalesN/A386.541,258.8298.06Price / CashN/A179.8139.0436.42Price / Book-0.534.406.295.90Net Income-$1M-$42.42M$118.56M$224.79M TradeUP Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPTDTradeUP AcquisitionN/A$0.84+5.0%N/A-38.3%$1.82MN/A0.002,021BCLIBrainstorm Cell Therapeutics4.5024 of 5 stars$1.22+1.7%N/A-57.8%$6.49MN/A-0.3540Analyst DowngradeShort Interest ↓High Trading VolumeONVOOrganovo0.7096 of 5 stars$0.40flatN/A-74.8%$6.13M$110,000.00-0.3820Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageKLTOKlotho NeurosciencesN/A$0.33-5.8%N/AN/A$5.65MN/A0.00N/AUpcoming EarningsGap DownCELZCreative Medical Technology1.8198 of 5 stars$2.90+3.2%N/A-36.7%$5.08M$10,000.00-0.765Short Interest ↓News CoveragePositive NewsBCDABioCardia2.7233 of 5 stars$2.30+1.8%N/A-60.7%$4.89M$428,000.00-0.4316Analyst ForecastShort Interest ↑News CoverageFRTXFresh Tracks TherapeuticsN/A$0.74flatN/A-22.6%$4.42M$10.06M-0.5220TTNPTitan Pharmaceuticals1.7116 of 5 stars$4.53+8.6%N/A-46.8%$3.99M$180,000.000.0010Short Interest ↓CHROChromocell TherapeuticsN/A$0.68+3.0%N/AN/A$3.92MN/A0.004Gap DownGENEGenetic Technologies0.1043 of 5 stars$0.77flatN/AN/A$3.71M$5.03M0.0050Short Interest ↑ALBTAvalon GloboCare0.9644 of 5 stars$3.42+4.6%N/A-64.7%$3.65M$1.30M-0.175Short Interest ↓ Related Companies and Tools Related Companies Brainstorm Cell Therapeutics Alternatives Organovo Alternatives Klotho Neurosciences Alternatives Creative Medical Technology Alternatives BioCardia Alternatives Fresh Tracks Therapeutics Alternatives Titan Pharmaceuticals Alternatives Chromocell Therapeutics Alternatives Genetic Technologies Alternatives Avalon GloboCare Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UPTD) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TradeUP Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share TradeUP Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UPTD Stock Alerts